Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$7.89 - $17.88 $2.33 Million - $5.28 Million
-295,436 Reduced 56.79%
224,763 $2.38 Million
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $10.5 Million - $17.9 Million
-907,178 Reduced 63.56%
520,199 $8.46 Million
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $504,150 - $697,153
-45,094 Reduced 3.06%
1,427,377 $19.8 Million
Q3 2021

Nov 15, 2021

SELL
$14.21 - $17.65 $1.25 Million - $1.56 Million
-88,259 Reduced 5.65%
1,472,471 $21.2 Million
Q2 2021

Aug 16, 2021

BUY
$9.5 - $17.24 $8 Million - $14.5 Million
842,000 Added 117.15%
1,560,730 $24.7 Million
Q1 2021

May 17, 2021

BUY
$7.37 - $13.61 $5.3 Million - $9.78 Million
718,730 New
718,730 $7.31 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Bain Capital Public Equity Management Ii, LLC Portfolio

Follow Bain Capital Public Equity Management Ii, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bain Capital Public Equity Management Ii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bain Capital Public Equity Management Ii, LLC with notifications on news.